The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 08, 2010
Filed:
Nov. 22, 2002
Frank Tegtmeier, Grevenbroich, DE;
Frans Eduard Janssens, Bonheiden, BE;
Joseph Elisabeth Leenaerts, Rijkevorsel, BE;
Koenraad Arthur Van Rossem, Vosselaar, BE;
Manuel Jesús Alcázar-vaca, Toledo, ES;
Pedro Martínez-jiménez, Madrid, ES;
José Manuel Bartolomé-nebreda, Toledo, ES;
Antonio Gómez-sánchez, Toledo, ES;
Francisco Javier Fernández-gadea, Toledo, ES;
Jozef Leo Henri Van Reempts, Geel, BE;
Frank Tegtmeier, Grevenbroich, DE;
Frans Eduard Janssens, Bonheiden, BE;
Joseph Elisabeth Leenaerts, Rijkevorsel, BE;
Koenraad Arthur van Rossem, Vosselaar, BE;
Manuel Jesús Alcázar-Vaca, Toledo, ES;
Pedro Martínez-Jiménez, Madrid, ES;
José Manuel Bartolomé-Nebreda, Toledo, ES;
Antonio Gómez-Sánchez, Toledo, ES;
Francisco Javier Fernández-Gadea, Toledo, ES;
Jozef Leo Henri Van Reempts, Geel, BE;
Janssen Pharmaceutica, NV., Beerse, BE;
Abstract
The invention concerns a novel histamine receptor antagonist and the use of an histamine receptor antagonist for the reduction of intracranial pressure (ICP), in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemida, in particular caused by brain injury, more in particular caused by traumatic (TBI) and non-traumatic brain injury. The novel compounds comprise compounds according to the general Formula (I) the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof and the N-oxide form thereof. In particular, the preferred compound is 3-[2-[4-(11,12-dihydro-6H-benzimidazo[2,1-b][3]benzazepin-6-yl)-2-(phenyl-methyl)-1-piperidinyl]ethyl]-2,10-dimethyl pyrimido[1,2-α]benzimidazol-4(10H)-one, the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof and the N-oxide form thereof. Also claimed is the novel use of commercially available histamine H1-and H2-receptor antagonists for the reduction of intracranial pressure (ICP).